AOD-9604 vs. Retatrutide After a Tirzepatide Plateau

Mentions of brand or product names are for identification only and do not constitute endorsement.

The tirzepatide plateau is a familiar wall. Patients lose 15 to 20 percent of body weight, then the scale stops. Appetite suppression fades. Food noise returns. The question becomes what to add or switch to when the GLP-1/GIP combo has run its course. Two names keep surfacing in peptide forums and clinical pipelines: AOD-9604, a fragment of human growth hormone, and retatrutide, a triple agonist still in phase 3 trials. They hit different nodes. AOD-9604 is a lipolysis signal with no direct incretin activity. Retatrutide adds glucagon receptor agonism to GLP-1 and GIP. That difference matters for metabolic flexibility, the ability to shift between fat oxidation and glucose use without crashing energy or muscle. This piece compares the two from a research-frame perspective, not a dosing guide. We look at what each pathway does, what the data shows, and what a plateau actually tells you about receptor desensitization versus energy expenditure. The honest answer is not one or the other. It is about which missing signal your plateau represents.

What We'd Want to See in a Plateau Rescue Agent

After tirzepatide stalls, the ideal add-on would do three things. First, restore fat oxidation without further suppressing appetite, since appetite is already blunted. Second, preserve lean mass, because rapid loss often includes muscle. Third, improve insulin sensitivity in peripheral tissues, not just the pancreas. AOD-9604 checks the first two on paper. The hGH fragment 177-191 selectively stimulates lipolysis in animal models, with less effect on IGF-1 or blood sugar than full growth hormone. Retatrutide checks the first and third. Its glucagon component increases energy expenditure and hepatic fat oxidation, while GLP-1 and GIP handle glucose control. The ideal agent would also avoid tachyphylaxis. GLP-1 receptors downregulate over months. AOD-9604 works through a different receptor, the beta-3 adrenergic pathway in adipocytes, so it may not cross-desensitize. Retatrutide still leans on GLP-1, but the glucagon add-on may offset receptor fatigue. That is the theoretical appeal.

What We Have: AOD-9604's Lipolytic Profile

AOD-9604 is the C-terminal fragment of growth hormone, amino acids 177-191. Early work by Frank Ng at Monash University showed it retains the fat-burning action of GH without the diabetogenic effects. In obese Zucker rats, AOD-9604 reduced body fat by 50 percent over 19 days, while glucose tolerance actually improved. Human trials are thinner. A 12-week study in obese adults found no significant weight loss versus placebo at 1 mg daily. That killed the oral formulation. But subcutaneous use at higher doses remains common in peptide clinics, and anecdotal reports describe a slow, steady fat loss, especially in stubborn areas. The mechanism is not incretin-based. AOD-9604 binds to a receptor on fat cells that activates hormone-sensitive lipase. It does not raise cAMP in the same way as clenbuterol, so heart rate and anxiety are less of an issue. For a patient stuck on tirzepatide, adding AOD-9604 is like adding a second engine that burns fat directly, while the GLP-1 keeps calories low. The question is whether that engine is strong enough to matter.

What We Have: Retatrutide's Triple Agonism

Retatrutide (LY3437943) is a single peptide that activates GLP-1, GIP, and glucagon receptors. In a phase 2 trial published in the New England Journal of Medicine, the highest dose produced 24.2 percent body weight reduction at 48 weeks. That exceeds tirzepatide's phase 3 results at similar time points. The glucagon component is the differentiator. Glucagon increases hepatic glucose output, which sounds counterproductive, but it also boosts energy expenditure and fat oxidation. In the context of GLP-1-mediated appetite suppression, the net effect is more fat burned per calorie eaten. Retatrutide also improved liver fat and lipid profiles more than GLP-1 alone. For a tirzepatide plateau, retatrutide offers a receptor-level upgrade. The GLP-1 and GIP components are familiar, but the glucagon add-on may overcome desensitization by recruiting a new pathway. The risk is tolerability. Glucagon agonism can cause nausea and increased heart rate in some patients. And retatrutide is not approved yet, so access is limited to trials or research channels. Still, the data points to a more complete metabolic reset than adding a lipolytic fragment.

What's Missing: Direct Head-to-Head Data

No published trial compares AOD-9604 to retatrutide. They occupy different evidence tiers. Retatrutide has phase 2 randomized controlled data. AOD-9604 has animal studies, one failed oral trial, and a large body of anecdotal use. That asymmetry makes direct comparison difficult. We can infer from mechanisms. AOD-9604 increases lipolysis but does not improve insulin sensitivity or reduce appetite. Retatrutide does all three, plus it lowers liver fat. For a patient who plateaued on tirzepatide, the missing piece is often energy expenditure adaptation. The body lowers its metabolic rate after weight loss. AOD-9604 may not reverse that. Retatrutide's glucagon component might. But retatrutide also carries more side effect risk and is harder to obtain. What is missing is a trial that takes tirzepatide non-responders and randomizes them to AOD-9604, retatrutide, or placebo. Until then, the choice is based on pharmacology, not outcomes. And pharmacology suggests retatrutide is the more complete answer for metabolic flexibility, while AOD-9604 is a narrower tool for stubborn fat.

How to Read the Plateau: Receptor Fatigue vs. Energy Gap

A tirzepatide plateau can mean two different things. One, the GLP-1 and GIP receptors have downregulated, so appetite suppression is weaker. Two, the body has adapted by lowering basal metabolic rate, so even with the same calorie intake, weight loss stops. The first problem calls for a different incretin or a higher dose. The second calls for an agent that raises energy expenditure. AOD-9604 addresses neither directly. It increases fat mobilization, but if total energy expenditure is low, the mobilized fat may be re-esterified. Retatrutide addresses both. Its GLP-1 component can be titrated to restore appetite suppression, and its glucagon component raises energy expenditure. That is why retatrutide is often framed as the next step after tirzepatide. Some patients add AOD-9604 to tirzepatide and see a few more pounds lost, but the effect is usually modest. Others switch to retatrutide and see a second wave of loss. The plateau itself is a diagnostic clue. If food noise is back, the incretin pathway needs help. If appetite is still suppressed but weight is stuck, the problem is metabolic rate. Retatrutide targets both. AOD-9604 targets neither, at least not directly.

The Honest Answer: Retatrutide for Flexibility, AOD-9604 for Stubborn Fat

For a patient who hit a tirzepatide plateau, retatrutide offers better metabolic flexibility on paper. It recruits glucagon to raise energy expenditure, improves insulin sensitivity, and lowers liver fat. The phase 2 data shows weight loss beyond what tirzepatide achieved. AOD-9604 is a lipolysis enhancer with a cleaner side effect profile, but its human efficacy is unproven at scale. It may help with localized fat deposits or as a maintenance adjunct, but it is not a plateau breaker. The honest answer is that retatrutide is the more logical next step for most patients, assuming access and tolerability. AOD-9604 is a niche tool for those who cannot tolerate incretins or want to target specific fat areas. Some clinicians combine them, using retatrutide for the metabolic reset and AOD-9604 for stubborn fat, but that is off-label and data-free. The plateau is a signal that the current pathway is exhausted. Retatrutide adds a new pathway. AOD-9604 adds a different one, but a weaker one. For metabolic flexibility, the triple agonist wins. For a gentle nudge, the fragment has a place. The choice depends on what the plateau is telling you.

Mentions of brand or product names are for identification only and do not constitute endorsement.